CHRS – Coherus BioSciences, Inc.
Coherus Oncology, Inc.CHRS
$0.7431Name : Coherus Oncology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $86,149,808.00
EPSttm : 0.44
Coherus Oncology, Inc.
$0.7431
1.43%$0.0105Float Short %
30.3
Margin Of Safety %
62
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.18
EPS Last/This Y
-1.24
EPS This/Next Y
0.31
Price
0.74
Target Price
4.68
Analyst Recom
2
Performance Q
-12.68
Relative Volume
1.13
Beta
0.87
Ticker: CHRS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | CHRS | 0.766 | 0.06 | 0.00 | 10002 |
| 2025-06-03 | CHRS | 0.78 | 0.06 | 0.00 | 10002 |
| 2025-06-04 | CHRS | 0.7911 | 0.06 | 0.00 | 10098 |
| 2025-06-05 | CHRS | 0.8025 | 0.06 | 0.00 | 10099 |
| 2025-06-06 | CHRS | 0.8282 | 0.06 | 0.00 | 10099 |
| 2025-06-09 | CHRS | 0.8526 | 0.06 | 0.04 | 10107 |
| 2025-06-10 | CHRS | 0.8056 | 0.06 | 0.07 | 10185 |
| 2025-06-11 | CHRS | 0.8094 | 0.06 | 0.00 | 10808 |
| 2025-06-12 | CHRS | 0.7923 | 0.06 | 0.00 | 11037 |
| 2025-06-13 | CHRS | 0.7596 | 0.06 | 0.29 | 11038 |
| 2025-06-16 | CHRS | 0.7784 | 0.06 | 0.00 | 11039 |
| 2025-06-17 | CHRS | 0.7587 | 0.06 | 0.00 | 11063 |
| 2025-06-18 | CHRS | 0.7592 | 0.06 | 0.01 | 11079 |
| 2025-06-20 | CHRS | 0.76 | 0.06 | 0.13 | 11210 |
| 2025-06-23 | CHRS | 0.7276 | 0.06 | 0.00 | 10550 |
| 2025-06-24 | CHRS | 0.7662 | 0.06 | 0.00 | 10785 |
| 2025-06-25 | CHRS | 0.7211 | 0.06 | 0.00 | 10880 |
| 2025-06-26 | CHRS | 0.7323 | 0.06 | 0.00 | 10869 |
| 2025-06-27 | CHRS | 0.7424 | 0.06 | 0.00 | 10864 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | CHRS | 0.76 | -97.6 | -142.9 | -1.11 |
| 2025-06-03 | CHRS | 0.78 | -97.6 | -143.6 | -1.11 |
| 2025-06-04 | CHRS | 0.79 | -97.6 | -143.6 | -1.11 |
| 2025-06-05 | CHRS | 0.81 | -97.6 | -143.5 | -1.11 |
| 2025-06-06 | CHRS | 0.83 | -97.6 | -143.8 | -0.99 |
| 2025-06-09 | CHRS | 0.85 | -79.5 | -144.0 | -0.99 |
| 2025-06-10 | CHRS | 0.81 | -79.5 | -142.0 | -0.99 |
| 2025-06-11 | CHRS | 0.81 | -79.5 | -143.3 | -0.99 |
| 2025-06-12 | CHRS | 0.79 | -79.5 | -142.9 | -0.99 |
| 2025-06-13 | CHRS | 0.77 | -79.5 | -142.5 | -0.99 |
| 2025-06-16 | CHRS | 0.78 | -79.5 | -143.9 | -0.99 |
| 2025-06-17 | CHRS | 0.75 | -79.5 | -142.4 | -0.99 |
| 2025-06-18 | CHRS | 0.77 | -79.5 | -143.4 | -0.99 |
| 2025-06-20 | CHRS | 0.75 | -79.5 | -142.5 | -0.99 |
| 2025-06-23 | CHRS | 0.73 | -79.5 | -142.6 | -0.99 |
| 2025-06-24 | CHRS | 0.77 | -79.5 | -144.4 | -0.99 |
| 2025-06-25 | CHRS | 0.72 | -79.5 | -142.1 | -0.99 |
| 2025-06-26 | CHRS | 0.73 | -79.5 | -143.4 | -0.99 |
| 2025-06-27 | CHRS | 0.74 | -79.5 | -143.3 | -0.99 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | CHRS | -2.13 | -5.57 | 29.75 |
| 2025-06-03 | CHRS | -2.13 | -5.57 | 29.72 |
| 2025-06-04 | CHRS | -2.17 | -5.57 | 29.72 |
| 2025-06-05 | CHRS | -2.17 | -5.57 | 29.72 |
| 2025-06-06 | CHRS | -2.17 | -5.57 | 29.72 |
| 2025-06-09 | CHRS | -2.17 | -5.56 | 29.72 |
| 2025-06-10 | CHRS | -2.17 | -5.56 | 29.72 |
| 2025-06-11 | CHRS | -2.17 | -5.56 | 29.20 |
| 2025-06-12 | CHRS | -2.17 | -5.56 | 29.20 |
| 2025-06-13 | CHRS | -2.17 | -5.56 | 29.20 |
| 2025-06-16 | CHRS | -2.17 | -5.56 | 30.86 |
| 2025-06-18 | CHRS | -0.94 | -5.56 | 30.86 |
| 2025-06-20 | CHRS | -0.94 | -5.56 | 30.86 |
| 2025-06-23 | CHRS | -0.94 | -6.28 | 30.86 |
| 2025-06-24 | CHRS | -0.94 | -6.28 | 30.86 |
| 2025-06-25 | CHRS | -0.94 | -6.28 | 30.86 |
| 2025-06-26 | CHRS | -0.94 | -6.28 | 30.30 |
| 2025-06-27 | CHRS | -0.94 | -6.28 | 30.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.41
Avg. EPS Est. Current Quarter
-0.25
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
-0.94
Institutional Transactions
-6.28
Beta
0.87
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
12
Fair Value
1.2
Quality Score
30
Growth Score
43
Sentiment Score
2
Actual DrawDown %
96.7
Max Drawdown 5-Year %
-96.9
Target Price
4.68
P/E
Forward P/E
PEG
P/S
0.44
P/B
P/Free Cash Flow
172.29
EPS
-1.13
Average EPS Est. Cur. Y
-0.99
EPS Next Y. (Est.)
-0.68
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-66.3
Relative Volume
1.13
Return on Equity vs Sector %
47.5
Return on Equity vs Industry %
65.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.01
EBIT Estimation
-143.3
Coherus Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 221
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
stock quote shares CHRS – Coherus BioSciences, Inc. Stock Price stock today
news today CHRS – Coherus BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CHRS – Coherus BioSciences, Inc. yahoo finance google finance
stock history CHRS – Coherus BioSciences, Inc. invest stock market
stock prices CHRS premarket after hours
ticker CHRS fair value insiders trading